Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome).

Strassburg CP.

Best Pract Res Clin Gastroenterol. 2010 Oct;24(5):555-71. doi: 10.1016/j.bpg.2010.07.007. Review.

PMID:
20955959
2.

Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs.

van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, Kenworthy KE, Schinkel AH.

J Clin Invest. 2010 Aug;120(8):2942-52. doi: 10.1172/JCI42168. Epub 2010 Jul 19.

3.

Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.

Treviño LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, Chan D, Sparreboom A, Giacomini KM, Pui CH, Evans WE, Relling MV.

J Clin Oncol. 2009 Dec 10;27(35):5972-8. doi: 10.1200/JCO.2008.20.4156. Epub 2009 Nov 9.

4.

Impact of OATP transporters on pharmacokinetics.

Kalliokoski A, Niemi M.

Br J Pharmacol. 2009 Oct;158(3):693-705. doi: 10.1111/j.1476-5381.2009.00430.x. Epub 2009 Sep 25. Review.

5.

Interaction of porphyrins with human organic anion transporting polypeptide 1B1.

Campbell SD, Lau WF, Xu JJ.

Chem Biol Interact. 2009 Nov 10;182(1):45-51. doi: 10.1016/j.cbi.2009.06.010. Epub 2009 Jun 26.

PMID:
19560444
6.

Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia.

Sanna S, Busonero F, Maschio A, McArdle PF, Usala G, Dei M, Lai S, Mulas A, Piras MG, Perseu L, Masala M, Marongiu M, Crisponi L, Naitza S, Galanello R, Abecasis GR, Shuldiner AR, Schlessinger D, Cao A, Uda M.

Hum Mol Genet. 2009 Jul 15;18(14):2711-8. doi: 10.1093/hmg/ddp203. Epub 2009 May 6.

7.

Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.

Vlaming ML, Pala Z, van Esch A, Wagenaar E, van Tellingen O, de Waart DR, Oude Elferink RP, van de Wetering K, Schinkel AH.

Clin Cancer Res. 2008 Dec 15;14(24):8152-60. doi: 10.1158/1078-0432.CCR-08-1609.

8.

Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1).

van de Steeg E, van der Kruijssen CM, Wagenaar E, Burggraaff JE, Mesman E, Kenworthy KE, Schinkel AH.

Drug Metab Dispos. 2009 Feb;37(2):277-81. doi: 10.1124/dmd.108.024315. Epub 2008 Nov 20.

9.

Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.

Takane H, Kawamoto K, Sasaki T, Moriki K, Moriki K, Kitano H, Higuchi S, Otsubo K, Ieiri I.

Cancer Chemother Pharmacol. 2009 May;63(6):1165-9. doi: 10.1007/s00280-008-0864-x. Epub 2008 Nov 8.

PMID:
18998132
10.

Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family.

Hagenbuch B, Gui C.

Xenobiotica. 2008 Jul;38(7-8):778-801. doi: 10.1080/00498250801986951 . Review.

PMID:
18668430
11.

SLCO1B1 variants and statin-induced myopathy--a genomewide study.

SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R.

N Engl J Med. 2008 Aug 21;359(8):789-99. doi: 10.1056/NEJMoa0801936. Epub 2008 Jul 23.

12.

Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies.

Ghibellini G, Leslie EM, Pollack GM, Brouwer KL.

Pharm Res. 2008 Aug;25(8):1851-60. doi: 10.1007/s11095-008-9597-0. Epub 2008 May 30.

13.

Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15.

Kim SR, Saito Y, Sai K, Kurose K, Maekawa K, Kaniwa N, Ozawa S, Kamatani N, Shirao K, Yamamoto N, Hamaguchi T, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Minami H, Ohtsu A, Saijo N, Sawada J.

Drug Metab Pharmacokinet. 2007 Dec;22(6):456-61.

14.

Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes.

van Waterschoot RA, van Herwaarden AE, Lagas JS, Sparidans RW, Wagenaar E, van der Kruijssen CM, Goldstein JA, Zeldin DC, Beijnen JH, Schinkel AH.

Mol Pharmacol. 2008 Mar;73(3):1029-36. Epub 2007 Dec 21.

15.

OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation.

Zhang W, He YJ, Gan Z, Fan L, Li Q, Wang A, Liu ZQ, Deng S, Huang YF, Xu LY, Zhou HH.

Clin Exp Pharmacol Physiol. 2007 Dec;34(12):1240-4.

PMID:
17973861
16.

Rotor-type hyperbilirubinaemia has no defect in the canalicular bilirubin export pump.

Hrebícek M, Jirásek T, Hartmannová H, Nosková L, Stránecký V, Ivánek R, Kmoch S, Cebecauerová D, Vítek L, Mikulecký M, Subhanová I, Hozák P, Jirsa M.

Liver Int. 2007 May;27(4):485-91.

PMID:
17403188
17.

Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.

Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Elferink RP, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, Schellens JH, Schinkel AH.

J Pharmacol Exp Ther. 2006 Jul;318(1):319-27. Epub 2006 Apr 12.

18.

Pharmacogenomics of human OATP transporters.

König J, Seithel A, Gradhand U, Fromm MF.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Mar;372(6):432-43. Epub 2006 Mar 9. Review.

PMID:
16525793
19.

Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides.

Zelcer N, van de Wetering K, de Waart R, Scheffer GL, Marschall HU, Wielinga PR, Kuil A, Kunne C, Smith A, van der Valk M, Wijnholds J, Elferink RO, Borst P.

J Hepatol. 2006 Apr;44(4):768-75. Epub 2005 Aug 9.

PMID:
16225954
20.

Drug bioactivation, covalent binding to target proteins and toxicity relevance.

Zhou S, Chan E, Duan W, Huang M, Chen YZ.

Drug Metab Rev. 2005;37(1):41-213. Review.

PMID:
15747500

Supplemental Content

Support Center